GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
📊
AI Sentiment
Positive
7/10
- Home
- HCM
as of 12-04-2025 3:59pm EST
$14.13
$0.13
-0.91%
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Chart Type:
Time Range:
| Founded: | 2000 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.6B | IPO Year: | N/A |
| Target Price: | $13.75 | AVG Volume (30 days): | 29.0K |
| Analyst Decision: | Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.51 - $19.50 | Next Earning Date: | 08-07-2025 |
| Revenue: | $602,197,000 | Revenue Growth: | -1.41% |
| Revenue Growth (this year): | -2.93% | Revenue Growth (next year): | 15.54% |
Latest HUTCHMED (China) Limited News
HCM Breaking Stock News: Dive into HCM Ticker-Specific Updates for Smart Investing
Compare HCM vs Leading Stocks
See how HCM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HCM HUTCHMED (China) Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.